After an extensive search, Perth Blood Institute (PBI) is pleased to announce David Sneddon as the organisation’s new CEO. David brings a wealth of senior executive leadership experience, commercial strength, and interpersonal attributes to lead PBI into the future.

Prior to joining PBI, David was the CEO of ARL Group, Western Australia’s leading chemical, occupational hygiene, microbiological and molecular diagnostics laboratory group.

 “I am delighted to join PBI at such an important time in its development and I look forward to growing PBI’s Clinical Trials Unit and Research Division, and expanding PBI’s national and global footprint,” David says.

David’s journey with PBI goes back many years, having been under the care of Professor Ross Baker for almost two decades, following a Deep Vein Thrombosis (DVT) in 2004, and in 2008 a subsequent DVT and near fatal Pulmonary Embolism (PE), a blood clot in the lung.

“As a result of my life-altering experience, I have a passion to see advancements in translational medical research into blood disorders and cutting-edge clinical trials that can usher in new treatments and therapies for people living with blood disorders,” David explains.

David takes this role as PBI celebrates its 10th anniversary next year. “PBI can be very proud of what it has achieved to date, and this provides a strong foundation to build upon. We are fully committed to PBI’s mission to prevent, treat and cure blood disorders, and our strategy is to achieve this through combining the best of medical research and clinical trials along with a heighted development and commercial focus,” David continues.

Please join us in welcoming David to the team. Visit David's Story if you would like to read more about David’s blood disorder journey.

Professor Ross Baker comments: “On behalf of the PBI Board, we are excited about the appointment of David to this pivotal role at PBI and we are looking forward to the many opportunities that are ahead of us, particularly in reaching our milestone of 10 years in operation in 2023.”